BOULDER, Colo., June 16, 2016 /PRNewswire/ -- Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer's disease, today announced that Dr. Charles Stacey, President and CEO, will present an overview of the company at the JMP Securities Life Science Conference.
About Accera
Accera, Inc. is a clinical-stage biotechnology company based in Boulder, Colo., that is developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease. For more information, visit www.accerapharma.com.
Follow Accera on Twitter at twitter.com/accerainc.
Accera Media Contacts:
Todd Davenport, Ph.D.
(212) 845-4235
todd.davenport@russopartnersllc.com
David Schull
(212) 845-4271
(858) 717-2310 Mobile
david.schull@russopartnersllc.com
SOURCE Accera, Inc.